Is Choksi Laborator overvalued or undervalued?

As of 10 October 2025, the valuation grade for Choksi Laborator has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 82.47, an EV to EBITDA of 13.39, and a PEG ratio of 2.92, which suggest that while the company has high earnings potential, its current market valuation may not fully reflect this potential.
In comparison to its peers, Choksi Laborator's PE ratio is lower than that of Max Healthcare at 93.27 and Fortis Health at 86.96, both categorized as very expensive. Additionally, Apollo Hospitals, which is rated as attractive, has a PE ratio of 70.15, further supporting the notion that Choksi Laborator is undervalued relative to its peers. Notably, the company's stock has outperformed the Sensex significantly over the long term, with a 5-year return of 1516.01% compared to the Sensex's 103.66%, reinforcing the attractiveness of its current valuation.